Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
The importance of a robust clinical outcome assessment strategy in your clinical trial
At ICON, we understand the nuances involved in creating a COA strategy that not only meets regulatory standards but also resonates with patients and stakeholders alike.
-
How an eCOA library can reduce your study start up timelines
Learn about the benefits of developing an eCOA library and how a strong eCOA strategy can help reduce screenshot review step by five weeks.
-
A dynamic market: Trends transforming the future of obesity drug development
Learn about the future of obesity drug development and explore how GLP-1 drugs and multi-indication therapies are transforming treatment.
-
Submission strategies for combined studies in the EU
In this article we look at how an oncology study sponsor managed their submission process which spanned more than 30 countries, many in the EU.
-
Maximising clinical trial success with integrated language services
Translation management is a critical component in global clinical trials - accurate and culturally appropriate communication is non-negotiable. Learn the importance of integrated language services in clinical research.
-
The benefits of going big: Why small biotechs need large CRO partners
Small biotech companies can gain significant benefits by partnering with a big CRO – if it’s the right fit. We outline some of the benefits of strategic partnerships for cash-constrained biotech.
-
Accelerating ATMP and CGT: The importance of Regulatory CMC expertise in efficient biologics development
Discover how dedicated Regulatory CMC expertise benefits biologics development, ensuring compliance and efficiency, especially for innovative therapies like ATMPs and CGTs.
-
Why using COAs and DHTs together is the future of clinical research
Though both COAs and DHTs are tools used to evaluate a treatment’s impact, they often exist in separate spheres, rarely integrated. We argue that combining these two approaches in the same study can help researchers gather better data and improve the likelihood of regulatory approval.
-
Enhancing diversity in clinical trials
To fully assess the efficacy and safety of a therapeutic indication, clinical trials must evaluate populations that are representative of the treatment population, as different people may experience the same disease differently.
-
Unlocking the value of transparent healthcare data
In this blog, we'll explore how transparency in healthcare data can unlock its full potential. Discover why transparency matters and how Symphony Health’s approach ensures you get the most accurate, actionable insights.
-
Digital health: Why evaluating human factors is essential
With the rapidly evolving technology, digital health is transforming healthcare, emerging as a promising solution to reduce rising healthcare costs and improve patient care.
-
Digital health: Managing cybersecurity risks
When developing a new digital health device, as well as maintaining an existing device, securing the device from cybersecurity attacks is critical.
-
_drug_pill_thumbnail.jpg?crop=yes&w=210&h=209&itok=_mALi-Gt "pill_drug_reduction_thumbnail")
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
Explore the Inflation Reduction Act’s key points of impact on pharmaceutical companies and considerations to strategically evolve with the coming changes.
-
Medicare Part D Price Negotiations update – Widespread impact on the industry
The Inflation Reduction Act (IRA) and resulting Medicare Part D price negotiations promise widespread impact on the industry. For the first time in history, the government is empowered to negotiate drug pricing directly with manufacturers.
-
Utilising connected sensors to power diverse and equitable clinical trials
Our publication in Nature npj Digital Medicine outlines current evidence and a solution framework for diversity in research using digital health technologies.
-
Outcome Measures: Driving forward patient-centered clinical trials
ICON’s Outcome Measures service aims to drive forward patient-centered treatments while also helping sponsors increase the likelihood of regulatory approval.
-
Enabling a new way to select fit-for-purpose COAs to simplify clinical protocols
While digital health technologies are one piece of the clinical protocol puzzle, holistic protocol design requires more breadth.
-
Enhancing diversity in clinical trials with AI and human expertise
Explore how AI-enabled insights and data-driven site selection can play a key part in a multifaceted approach to diversity in clinical trials and benefit equity in healthcare by extension.
-
The rise of precision outcome measures
Precision outcome measures are the means by which to evaluate a meaningful change on the exact outcome of interest, regardless of tool or instrument.
-
Understanding China's 2024 NRDL: Key changes and their impact
This blog provides an overview of the NRDL’s history, highlights the key changes for 2024, and discusses the potential impact on both local and international pharmaceutical industries.